HighTower Advisors LLC Acquires 10,575 Shares of TransMedics Group, Inc. $TMDX

Key Points

• HighTower Advisors LLC increased its holdings in TransMedics Group, Inc. by 137.7% during the first quarter, owning approximately $1.23 million worth of shares after purchasing an additional 10,575 shares.
• Several analysts have given the stock an average rating of "Moderate Buy" with target prices ranging from $115.00 to $150.00, indicating confidence in the company's growth potential.
• TransMedics Group reported a quarterly earnings per share (EPS) of $0.92, significantly exceeding analyst expectations and reflecting a 37.7% year-over-year revenue increase.

HighTower Advisors LLC increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 137.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,257 shares of the company's stock after buying an additional 10,575 shares during the period. HighTower Advisors LLC owned about 0.05% of TransMedics Group worth $1,228,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Braidwell LP acquired a new position in TransMedics Group during the 4th quarter worth $57,493,000. Mackenzie Financial Corp boosted its holdings in shares of TransMedics Group by 73.0% in the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after buying an additional 349,403 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of TransMedics Group by 1,565.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock valued at $16,820,000 after buying an additional 253,624 shares during the period. Avidity Partners Management LP boosted its stake in TransMedics Group by 597.1% during the 4th quarter. Avidity Partners Management LP now owns 192,400 shares of the company's stock valued at $11,996,000 after purchasing an additional 164,800 shares during the period. Finally, Frontier Capital Management Co. LLC acquired a new position in TransMedics Group during the 4th quarter valued at about $9,415,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

TMDX has been the topic of a number of recent analyst reports. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Monday. Piper Sandler restated an "overweight" rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Morgan Stanley upped their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Finally, Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $123.00.

TransMedics Group Price Performance

Shares of TransMedics Group stock traded down $1.76 during mid-day trading on Friday, reaching $114.96. 665,572 shares of the stock were exchanged, compared to its average volume of 1,310,928. The company has a market cap of $3.92 billion, a price-to-earnings ratio of 59.57 and a beta of 2.09. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The firm has a 50-day simple moving average of $120.41 and a 200 day simple moving average of $102.52. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $172.78.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same quarter last year, the company posted $0.35 EPS. The firm's revenue for the quarter was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.